Siren L.L.C. Buys 1,990,617 Shares of Oric Pharmaceuticals, Inc. $ORIC

Siren L.L.C. lifted its stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 197.6% during the first quarter, Holdings Channel.com reports. The firm owned 2,998,192 shares of the company’s stock after acquiring an additional 1,990,617 shares during the period. Oric Pharmaceuticals accounts for about 1.1% of Siren L.L.C.’s portfolio, making the stock its 29th biggest position. Siren L.L.C.’s holdings in Oric Pharmaceuticals were worth $37,987,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in Oric Pharmaceuticals during the 1st quarter worth approximately $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Oric Pharmaceuticals by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after acquiring an additional 3,131 shares during the period. Goldman Sachs Group Inc. grew its stake in Oric Pharmaceuticals by 9.2% in the first quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock valued at $1,645,000 after acquiring an additional 24,778 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Oric Pharmaceuticals by 1,331.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock valued at $2,841,000 after acquiring an additional 473,600 shares in the last quarter. Finally, Jane Street Group LLC raised its position in shares of Oric Pharmaceuticals by 56.0% during the first quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock worth $174,000 after purchasing an additional 11,198 shares during the period. 95.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ORIC has been the subject of several research reports. Stifel Nicolaus started coverage on shares of Oric Pharmaceuticals in a research report on Friday, June 12th. They issued a “buy” rating and a $14.00 price target for the company. Wedbush decreased their target price on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, April 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Oric Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $19.27.

Oric Pharmaceuticals Stock Performance

NASDAQ:ORIC opened at $10.89 on Friday. Oric Pharmaceuticals, Inc. has a 52 week low of $7.23 and a 52 week high of $14.93. The firm has a 50-day moving average price of $9.31 and a two-hundred day moving average price of $10.28. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -7.56 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Monday, May 4th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). As a group, sell-side analysts forecast that Oric Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.